Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial

Psychoneuroendocrinology

Volumn 78, Issue , 2017, Pages 105-113

  Jha, Manish K ^a   Minhajuddin, Abu ^a   Gadad, Bharathi S ^a   Greer, Tracy ^a   Grannemann, Bruce ^a   Soyombo, Abigail ^a   Mayes, Taryn L ^a   Rush, A John ^b   Trivedi, Madhukar H ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Antidepressant response; Biomarker; C reactive protein; Depression; Inflammation

Indexed keywords

ALPHA 2 MACROGLOBULIN; AMFEBUTAMONE; C REACTIVE PROTEIN; ESCITALOPRAM; PLACEBO; SERUM AMYLOID P; ANTIDEPRESSANT AGENT; CITALOPRAM;

ADULT; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DRUG CHOICE; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; OUTPATIENT; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; REMISSION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; BLOOD; COMBINATION DRUG THERAPY; METABOLISM; SELF REPORT;

ADULT; ANTIDEPRESSIVE AGENTS; BUPROPION; C-REACTIVE PROTEIN; CITALOPRAM; DEPRESSIVE DISORDER; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; REMISSION INDUCTION; SELF REPORT; TREATMENT OUTCOME;

EID: 85011799055     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2017.01.023     Document Type: Article

References (49)

1. Arnow, B.A., Blasey, C., Williams, L.M., Palmer, D.M., Rekshan, W., Schatzberg, A.F., Etkin, A., Kulkarni, J., Luther, J.F., Rush, A.J., Depression subtypes in predicting antidepressant response: a report from the iSPOT-D trial. Am. J. Psychiatry 172 (2015), 743–750.
2. Ascher, J.A., Cole, J.O., Colin, J.N., Feighner, J.P., Ferris, R.M., Fibiger, H.C., Golden, R.N., Martin, P., Potter, W.Z., Richelson, E., et al. Bupropion: a review of its mechanism of antidepressant activity. J. Clin. Psychiatry 56 (1995), 395–401.
3. Brown, A.S., Sourander, A., Hinkka-Yli-Salomaki, S., McKeague, I.W., Sundvall, J., Surcel, H.M., Elevated maternal C-reactive protein and autism in a national birth cohort. Mol. Psychiatry 19 (2014), 259–264.
4. Brustolim, D., Ribeiro-dos-Santos, R., Kast, R.E., Altschuler, E.L., Soares, M.B., A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice. Int. Immunopharmacol. 6 (2006), 903–907.
5. Cremers, T.I., Flik, G., Folgering, J.H., Rollema, H., Stratford, R.E. Jr., Development of a rat plasma and brain extracellular fluid pharmacokinetic model for bupropion and hydroxybupropion based on microdialysis sampling, and application to predict human brain concentrations. Drug Metab. Dispos. 44 (2016), 624–633.
6. Danesh, J., Wheeler, J.G., Hirschfield, G.M., Eda, S., Eiriksdottir, G., Rumley, A., Lowe, G.D., Pepys, M.B., Gudnason, V., C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N. Engl. J. Med. 350 (2004), 1387–1397.
7. Dantzer, R., O'Connor, J.C., Freund, G.G., Johnson, R.W., Kelley, K.W., From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 9 (2008), 46–56.
8. Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E.K., Lanctot, K.L., A meta-analysis of cytokines in major depression. Biol. Psychiatry 67 (2010), 446–457.
9. Ebbinghaus, M., Gajda, M., Boettger, M.K., Schaible, H.-G., Bräuer, R., The anti-inflammatory effects of sympathectomy in murine antigen-induced arthritis are associated with a reduction of Th1 and Th17 responses. Ann. Rheum. Dis. 71 (2012), 253–261.
10. Eller, T., Vasar, V., Shlik, J., Maron, E., Pro-inflammatory cytokines and treatment response to escitaloprsam in major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry. 32 (2008), 445–450.
11. Emberson, J.R., Whincup, P.H., Morris, R.W., Walker, M., Lowe, G.D., Rumley, A., Extent of regression dilution for established and novel coronary risk factors: results from the British Regional Heart Study. Eur. J. Cardiovasc. Prev. Rehab. 11:2 (2004), 125–134.
12. Fawcett, J., Rush, A.J., Vukelich, J., Diaz, S.H., Dunklee, L., Romo, P., Yarns, B.C., Escalona, R., Clinical experience with high-dosage pramipexole in patients with treatment-resistant depressive episodes in unipolar and bipolar depression. Am. J. Psychiatry 173 (2016), 107–111.
13. Felger, J.C., The role of dopamine in inflammation-associated depression: mechanisms and therapeutic implications. Curr. Top. Behav. Neurosci., 2016, 10.1007/7854_2016_13.
14. Greeson, J.M., Gettes, D.R., Spitsin, S., Dubé, B., Benton, T.D., Lynch, K.G., Douglas, S.D., Evans, D.L., The selective serotonin reuptake inhibitor citalopram decreases human immunodeficiency virus receptor and coreceptor expression in immune cells. Biol. Psychiatry 80 (2016), 33–39.
15. Haapakoski, R., Mathieu, J., Ebmeier, K.P., Alenius, H., Kivimaki, M., Cumulative meta-analysis of interleukins 6 and 1beta: tumour necrosis factor alpha and C-reactive protein in patients with major depressive disorder. Brain Behav. Immun. 49 (2015), 206–215.
16. Hannestad, J., DellaGioia, N., Bloch, M., The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 36 (2011), 2452–2459.
17. Harley, J., Luty, S., Carter, J., Mulder, R., Joyce, P., Elevated C-reactive protein in depression: a predictor of good long-term outcome with antidepressants and poor outcome with psychotherapy. J. Psychopharmacol. 24 (2010), 625–626.
18. Kaptoge, S., Di Angelantonio, E., Lowe, G., Pepys, M.B., Thompson, S.G., Collins, R., Danesh, J., C-reactive protein concentration and risk of coronary heart disease stroke, and mortality: an individual participant meta-analysis. Lancet 375 (2010), 132–140.
19. Khera, A., McGuire, D.K., Murphy, S.A., Stanek, H.G., Das, S.R., Vongpatanasin, W., Wians, J.F.H., Grundy, S.M., de Lemos, J.A., Race and gender differences in C-reactive protein levels. J. Am. Coll. Cardiol. 46 (2005), 464–469.
20. Kubera, M., Simbirtsev, A., Mathison, R., Maes, M., Effects of repeated fluoxetine and citalopram administration on cytokine release in C57BL/6 mice. Psychiatry Res. 96 (2000), 255–266.
21. Lamers, F., Bot, M., Jansen, R., Chan, M.K., Cooper, J.D., Bahn, S., Penninx, B.W.J.H., Serum proteomic profiles of depressive subtypes. Transl. Psychiatry, 6, 2016, e851.
22. Lieberknecht, V., Junqueira, S.C., Cunha, M.P., Barbosa, T.A., de Souza, L.F., Coelho, I.S., Santos, A.R., Rodrigues, A.L., Dafre, A.L., Dutra, R.C., Pramipexole, a dopamine D2/D3 receptor-preferring agonist, prevents experimental autoimmune encephalomyelitis development in mice. Mol. Neurobiol., 2016, 10.1007/s12035-016-9717-5.
23. Maes, M., Delanghe, J., Scharpe, S., Meltzer, H.Y., Cosyns, P., Suy, E., Bosmans, E., Haptoglobin phenotypes and gene frequencies in unipolar major depression. Am. J. Psychiatry 151 (1994), 112–116.
24. Martino, M., Rocchi, G., Escelsior, A., Fornaro, M., Immunomodulation mechanism of antidepressants: interactions between serotonin/norepinephrine balance and Th1/Th2 balance. Curr. Neuropharmacol. 10 (2012), 97–123.
25. McGrath, P.J., Khan, A.Y., Trivedi, M.H., Stewart, J.W., Morris, D.W., Wisniewski, S.R., Miyahara, S., Nierenberg, A.A., Fava, M., Rush, A.J., Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report. J. Clin. Psychiatry 69 (2008), 1847–1855.
26. Melnikov, M., Belousova, O., Murugin, V., Pashenkov, M., Boyко, A., The role of dopamine in modulation of Th-17 immune response in multiple sclerosis. J. Neuroimmunol. 292 (2016), 97–101.
27. O'Brien, S.M., Scully, P., Fitzgerald, P., Scott, L.V., Dinan, T.G., Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J. Psychiatr. Res. 41 (2007), 326–331.
28. Pepys, M.B., Hirschfield, G.M., C-reactive protein: a critical update. J. Clin. Invest. 111 (2003), 1805–1812.
29. Raison, C.L., Rutherford, R.E., Woolwine, B.J., Shuo, C., Schettler, P., Drake, D.F., Haroon, E., Miller, A.H., A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 70 (2013), 31–41.
30. Rethorst, C.D., Bernstein, I., Trivedi, M.H., Inflammation, obesity, and metabolic syndrome in depression: analysis of the 2009–2010 National Health and Nutrition Examination Survey (NHANES). J. Clin. Psychiatry 75 (2014), e1428–1432.
31. Ridker, P.M., Cardiology Patient Page: C-reactive protein: a simple test to help predict risk of heart attack and stroke. Circulation 108 (2003), e81–85.
32. Rush, A.J., Trivedi, M.H., Ibrahim, H.M., Carmody, T.J., Arnow, B., Klein, D.N., Markowitz, J.C., Ninan, P.T., Kornstein, S., Manber, R., Thase, M.E., Kocsis, J.H., Keller, M.B., The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol. Psychiatry 54 (2003), 573–583.
33. Rush, A.J., Bernstein, I.H., Trivedi, M.H., Carmody, T.J., Wisniewski, S., Mundt, J.C., Shores-Wilson, K., Biggs, M.M., Woo, A., Nierenberg, A.A., Fava, M., An evaluation of the quick inventory of depressive symptomatology and the hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report. Biol. Psychiatry 59 (2006), 493–501.
34. Rush, A.J., Trivedi, M.H., Wisniewski, S.R., Nierenberg, A.A., Stewart, J.W., Warden, D., Niederehe, G., Thase, M.E., Lavori, P.W., Lebowitz, B.D., McGrath, P.J., Rosenbaum, J.F., Sackeim, H.A., Kupfer, D.J., Luther, J., Fava, M., Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry 163 (2006), 1905–1917.
35. Rush, A.J., Trivedi, M.H., Stewart, J.W., Nierenberg, A.A., Fava, M., Kurian, B.T., Warden, D., Morris, D.W., Luther, J.F., Husain, M.M., Cook, I.A., Shelton, R.C., Lesser, I.M., Kornstein, S.G., Wisniewski, S.R., Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am. J. Psychiatry 168 (2011), 689–701.
36. Sacerdote, P., Bianchi, M., Panerai, A.E., Chlorimipramine and nortriptyline but not fluoxetine and fluvoxamine inhibit human polymorphonuclear cell chemotaxis In vitro. Gen. Pharmacol. 25 (1994), 409–412.
37. Schatzberg, A.F., DeBattista, C., Lazzeroni, L.C., Etkin, A., Greer, M., Murphy, J., Williams, L.M., ABCB1 genetic effects on antidepressant outcomes: a report from the iSPOT-D trial. Am. J. Psychiatry 172 (2015), 751–759.
38. Sheehan, D.V., Lecrubier, Y., Sheehan, K.H., Amorim, P., Janavs, J., Weiller, E., Hergueta, T., Baker, R., Dunbar, G.C., The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry, 1998.
39. Shelton, R.C., Falola, M., Li, L., Zajecka, J., Fava, M., Papakostas, G.I., The pro-inflammatory profile of depressed patients is (partly) related to obesity. J. Psychiatr. Res. 70 (2015), 91–97.
40. Shenoy, A.R., Dehmel, T., Stettner, M., Kremer, D., Kieseier, B.C., Hartung, H.P., Hofstetter, H.H., Citalopram suppresses thymocyte cytokine production. J. Neuroimmunol. 262 (2013), 46–52.
41. Strawbridge, R., Arnone, D., Danese, A., Papadopoulos, A., Herane Vives, A., Cleare, A.J., Inflammation and clinical response to treatment in depression: a meta-analysis. Eur. Neuropsychopharmacol. 25 (2015), 1532–1543.
42. Sung, S.C., Wisniewski, S.R., Balasubramani, G.K., Zisook, S., Kurian, B., Warden, D., Trivedi, M.H., Rush, A.J., Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED trial report. Psychol. Med. 43 (2013), 945–960.
43. Uher, R., Tansey, K.E., Dew, T., Maier, W., Mors, O., Hauser, J., Dernovsek, M.Z., Henigsberg, N., Souery, D., Farmer, A., McGuffin, P., An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. Am. J. Psychiatry 171 (2014), 1278–1286.
44. Verduijn, J., Milaneschi, Y., Schoevers, R.A., van Hemert, A.M., Beekman, A.T., Penninx, B.W., Pathophysiology of major depressive disorder: mechanisms involved in etiology are not associated with clinical progression. Transl. Psychiatry, 5, 2015, e649.
45. Warner-Schmidt, J.L., Vanover, K.E., Chen, E.Y., Marshall, J.J., Greengard, P., Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 9262–9267.
46. Wisniewski, S.R., Rush, A.J., Balasubramani, G.K., Trivedi, M.H., Nierenberg, A.A., Self-rated global measure of the frequency, intensity, and burden of side effects. J. Psychiatr. Pract. 12 (2006), 71–79.
47. Wium-Andersen, M., Ørsted, D., Nielsen, S., Nordestgaard, B., ELevated c-reactive protein levels, psychological distress, and depression in 73 131 individuals. JAMA Psychiatry 70 (2013), 176–184.
48. Woloshin, S., Schwartz, L.M., Distribution of C-reactive protein values in the United States. N. Engl. J. Med. 352 (2005), 1611–1613.
49. Yoshimura, R., Hori, H., Ikenouchi-Sugita, A., Umene-Nakano, W., Ueda, N., Nakamura, J., Higher plasma interleukin-6 (IL-6) level is associated with SSRI- or SNRI-refractory depression. Prog. Neuropsychopharmacol. Biol. Psychiatry. 33 (2009), 722–726.